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1682-606X/Copyright ª 2015, TaiwanAbstract Multidisciplinary teams (MDTs) are now widely accepted as a standard of quality
control and a model for various approaches to cancer care in many countries. Evidence has
shown that MDTs can improve clinical decision-making as well as the outcomes and experiences
of patients with various cancers. Adopting MDTs for treating patients with colorectal cancer
has considerably influenced current medical practice. Most of the decisions made by MDTs
are implemented, and preoperative evaluation can be achieved more completely with more
accurate preoperative staging. Patients who receive care under the guidance of MDTs have
higher rates of access to multimodal therapies than do patients who do not. In addition, pa-
thology reports are more likely to be of higher quality. In an MDT setting, adjuvant chemother-
apies are prescribed in a more suitable manner and overall survival is improved. An MDT can
determine whether patients with rectal cancer should first be treated surgically or receive
neoadjuvant therapy. MDTs considerably influence decisions regarding the choice of staging
modality and neoadjuvant treatment. However, results regarding the reduced rate of positive
circumferential resection margins and more favorable overall survival are controversial. In
conclusion, most of the influence of MDTs on current treatment for colorectal cancer is posi-
tive; therefore, establishing MDTs should be encouraged to enhance the quality of colorectal
cancer care.
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The multidisciplinary team (MDT) approach has been
adopted in various fields of medicine and patient care.
Because treatment options for cancer care have increased
rapidly in recent decades, establishing an MDT is crucial to
fulfilling the requirement of multimodal treatments in
current practice in cancer treatment. Establishing MDTs for
treating various cancers is encouraged in some countries
and is considered a standard of quality control in cancer
care. The influence of MDTs has been evaluated by several
researchers, but some controversial results have been ob-
tained. Therefore, clarifying the role of MDTs in cancer
treatment is essential. Here, we present a literature review
that focuses on the influence of MDTs in colorectal cancer
treatment.2. Definition of MDTs
An MDT is defined as “a group of people of different
healthcare disciplines, which meets together at a given
time (whether physically in one place, or by video or
teleconferencing) to discuss a given patient and who are
each able to contribute independently to the diagnostic
and treatment decisions about the patient”.1 Through
regular meetings and discussions within MDTs, healthcare
professionals can improve communication, cooperation,
and decision-making regarding cancer treatment.
In general, the composition of an MDT for cancer care
includes specialists from medical oncology, surgical
oncology, radiation oncology, pathology, diagnostic and
interventional radiology, palliative care, nursing pro-
fessionals, nutritionists, and social workers.2 The compo-
sition of an MDT may vary depending on the cancer type.3. MDTs in cancer care
Since 1996, the Department of Health of the UK has issued a
series of population-based publications on the improved
outcomes of patients with breast cancer, colorectal cancer,
lung cancer, gynecological cancer, and upper gastrointes-
tinal cancer.2 National standards and guidance for cancer
care were established in these publications, and the
establishment of MDTs has been a consistent recommenda-
tion in these reports and other publications since 1996.3e5
MDTs are now widely accepted as a model of various
approaches to cancer care in many other countries, such as
the USA,6e8 Canada,9 Australia,10,11 and some countries in
Europe12,13 and Asia.14 The effect of MDTs on more favor-
able patient selection and improved patient survival has
been demonstrated in patients with esophageal,15,16
gastric,16 pancreatic,17 lung,13,18 breast,7 and gynecologi-
cal cancers.14,19,20 The cancer-specific outcome is consid-
ered more favorable when patients are managed under MDT
care. Evidence has shown that MDTs can improve clinical
decision-making as well as the outcomes and experiences of
patients with various cancers.6,15,21 However, validating
the specific effects of MDTs on patient outcomes is chal-
lenging because most studies on MDTs are observational or
retrospective, and multiple concurrent advances occurregarding cancer treatment and care.2,22 Therefore, initi-
ating a randomized trial validating the effects of MDTs is
impossible.
4. MDTs in colorectal cancer treatment
The diagnosis and treatment of colorectal cancer have
rapidly developed in the past decade, and like other can-
cers, managing colorectal cancer through a single treat-
ment is difficult. After the 1995 CalmaneHine report was
presented in the UK, the implementation of an MDT
approach for colorectal cancer has been widely
accepted.4,23
Although some limitations regarding MDTs are empha-
sized in the literature,24e26 such as debates on decision-
making within MDTs, the costs of MDTs (extra hours and
workload for members attending MDT meetings, unnec-
essary discussion in routine cases), and the limitation of
discussion regarding elective cancer patients, MDTs have
been incorporated into government policies and guidelines.
In the USA, the American College of Surgeons Commission
on Cancer has included MDTs as a key program requirement
for colorectal cancer care. A project for optimizing rectal
cancer treatment has been initiated by the Optimizing
Surgical Treatment of Rectal Cancer (OSTRiCh) group, a
consortium of 18 healthcare institutions whose purpose is
to transform the delivery of rectal cancer care in the USA.27
Establishing MDTs and training MDT members to treat pa-
tients with rectal cancer are encouraged by the OSTRiCh
group. The German Cancer Society has provided certifica-
tion for oncological care institutions since 2003 and the
numbers of pretreatment and postoperative case pre-
sentations at MDT conferences are evaluation indicators for
colorectal cancer care.28 According to the 2013 bench-
marking report, the rate of pretreatment case pre-
sentations on primary-care patients with rectal carcinoma
or colon carcinoma at UICC Stage IV increased to 91.8% in
2012, and the rate of postoperative case presentations has
remained at an extremely high level of > 95% since 2010.28
In Taiwan, a certification program on the quality of
cancer care in hospitals was initiated by the National
Health Research Institutes in 2008.29 Establishing MDTs for
cancer care is required for certification.30 The results of
certification are available on a website for public access
and influence national health insurance payments by the
government. At Taipei Veterans General Hospital, Taipei,
Taiwan an MDT for colorectal cancer was established in
October 2007. The core members are surgeons, medical
oncologists, radiation oncologists, pathologists, diagnostic
and interventional radiologists, nurse specialists, and co-
ordinators. Regular weekly group meetings are held for
treatment planning. Initially, the group included colorectal
and hepatobiliary surgeons as team members, and because
of an increase in treatment demands for pulmonary meta-
static lesions, thoracic surgeons have been included since
October 2011.
4.1. Decision-making
Decisions regarding the choice of treatment may be
changed after MDT meetings, but not every decision can be
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systematic review, MDTs changed cancer management by
individual physicians in 2e52% of cases, whereas decisions
could not be implemented in 1e16% of cases.31 Wood et al32
examined the implementation of an MDT approach in the
decision-making process and reasons for disagreement in
colorectal cancer treatment. The authors demonstrated
that most colorectal MDT decisions were implemented and
onlyw10% of the decisions were not implemented in a total
of 201 consecutive treatment decisions. Furthermore, they
confirmed a colorectal MDT as an effective forum. In cases
of disagreement, the final treatment was always more
conservative than the initial treatment planned and pro-
vided by MDTs. The reasons for changes were mostly asso-
ciated with patients’ comorbidity, which was not
considered during meetings; moreover, treatment with a
palliative intent is another major reason for not following
MDT recommendations.
Ryan and Faragher25 prospectively assessed 197
consecutive cases presented to a colorectal MDT and
compared the plans made using routine care pathways and
those made at MDT meetings. The authors demonstrated
that discussing routine cases of colon cancer rarely changed
management (3.4%). Conversely, management changed in
50% of complex cases after MDT discussion. Topics that
commonly generated useful discussion were the preopera-
tive management of rectal cancer, management of meta-
static or recurrent disease, management of malignant
polyps, and patients for whom no written management
pathway was present to guide treatment. Only 4% of all
cases deviated from the proposed treatment because of
complex patient factors, poor prognostic features, patient
age, and medical comorbidity.25
These findings highlight the need of information on the
general health status of patients and their preference for
treatment, which should be available at MDT meetings.
Typically, MDT decisions are made by physician members
according to biomedical information and patient choice is
seldom considered in the decision-making process.31 Nurses
should attend MDT meetings because they can offer the
views of patients and the psychosocial aspects of care to
the meetings. When nurses are actively involved, the per-
formance of an MDT is apparently higher.34.2. Preoperative workup
Evidence has shown that implementing an MDT approach for
managing colorectal cancer can result in more complete
preoperative evaluations as well as higher rates of access to
multimodal therapies.33,34 When the preoperative tests
prescribed by the National Comprehensive Cancer Network
guidelines were considered, the proportion of patients with
colon cancer who underwent complete preoperative tests
was significantly higher under MDT care (91.7% vs. 27.5%,
p < 0.001), and this trend was also observed in patients
with rectal cancer (84.0% vs. 15.3%, p < 0.001). Differences
were observed in the rates of chest computed tomography
(CT) scan (95.0% vs. 37.1%, p < 0.001), carcinoembryonic
antigen testing (100% vs. 63.8%, p < 0.001), and transrectal
ultrasound for rectal cancer (88.0% vs. 37.7%, p < 0.001).34
Another study demonstrated that significantly morepatients underwent CT TNM staging when under the care of
an MDT (81.3% vs. 41.1%, p < 0.001).35 In a population-
based study in The Netherlands, magnetic resonance im-
aging (MRI) was used more often (p Z 0.001) and TNM
staging was more complete (p < 0.001) under the care of an
MDT.36
In addition to the completeness of preoperative workup,
staging accuracy also improves after an MDT approach has
been established. Radiological TNM staging according to CT
scans was compared with the final pathological stage be-
tween the periods before and after the establishment of an
MDT approach; CT TNM staging was more accurate in the
MDT group than in the pre-MDT group (64.0% vs. 45.9%,
p Z 0.044).354.3. Access to multimodal therapy for rectal cancer
The multimodal characteristics of different treatment ap-
proaches have rendered the treatment of rectal cancer
complex in current daily practice. Therefore, in many re-
spects, MDTs are crucial for treating patients with rectal
cancer. According to an international survey, regular MDT
meetings significantly influence decisions on the choice of
staging modality, neoadjuvant treatment, and several
other critical factors in the preoperative planning of rectal
cancer treatment.33
The main components of rectal cancer treatment
include: (1) total mesorectal excision; (2) assessment of the
quality of surgery by pathologists; (3) identification of pa-
tients at a high risk of local recurrence through imaging
techniques; (4) use of effective neoadjuvant and adjuvant
therapies, including radiotherapy and chemotherapy; and
(5) an MDT approach that identifies, coordinates, delivers,
and monitors the ideal treatment on an individual basis.27
An MDT approach enables distinguishing between patients
who should first be treated surgically and those who should
be offered neoadjuvant therapy.37 Thus, patients with
advanced disease (cT3 or Nþ), those with distal tumors,
and those who receive preoperative chemoradiotherapy are
more often discussed by MDTs.36 According to an interna-
tional survey involving 123 colorectal cancer centers in
North America, Europe, and Asia, departments with regular
MDT meetings were more likely to use MRI to determine
local staging and were more likely to encourage patients
with threatened circumferential resection margins to un-
dergo neoadjuvant treatment.33
In a survey by Levine et al,34 the proportion of patients
who underwent neoadjuvant therapy was significantly
higher for patients under MDT care (76% vs. 20%, p < 0.001).
This survey also included a subgroup analysis of patients
with Stages II and III disease, and the results showed that
patients under MDT care were more likely to undergo
neoadjuvant therapy (Stage II: 87.5% vs. 31.3%, p Z 0.03;
Stage III: 87.5% vs. 23.8%, p Z 0.003). However, contro-
versial results exist regarding MDT care. According to a
survey conducted in The Netherlands, the proportion of
patients with T2-3/M0 rectal cancer who received preop-
erative radiotherapy was not different between MDT and
control groups [odds ratio (OR) Z 0.98, 95% confidence
interval (CI) Z 0.96e1.14].23 Moreover, no difference was
observed in using preoperative chemoradiation for patients
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however, the actual numbers used to calculate the pro-
portion were not mentioned.23 In a survey in the UK, an
MDT score was calculated based on each unit’s adherence
to the criteria of the ideal colorectal cancer team. An in-
crease of 25% in the MDT score was initially associated with
a 58% increased odds of using preoperative radiotherapy for
rectal cancer, but after the collinearity of the MDT score
and time was considered, the effect of a 25% increase in the
MDT score on the use of preoperative radiotherapy was not
evident (OR Z 0.99, 95% CI Z 0.75e13.2).4
In addition to neoadjuvant treatment, conducting MDT
meetings for treating rectal cancer has resulted in a
reduced positive circumferential resection margin rate, a
lower rate of local recurrence, more effective evidence-
based care, and more favorable overall survival.38 In Burton
et al’s38 study, a higher positive rate (26%) of the circum-
ferential resection margin was observed in 62 patients who
underwent surgery alone without MRI-based MDT discussion
than in those who underwent surgery with MRI-based MDT
discussion (1%). Furthermore, the positive circumferential
resection margin rate decreased to 7% overall at 1 year of
follow-up after compulsory MDT discussion in 96% of pa-
tients with rectal cancer.38 However, a population-based
study showed that the overall positive rate of the circum-
ferential resection margin did not significantly differ be-
tween patients with and without MDT discussion (10% vs.
14%, p Z 0.392).36
For early rectal cancer, determining suitability for local
excision is a multifactorial decision that must consider
pathological factors, local and regional stages, and patient
comorbidities and desires. A retrospective study investi-
gated the influence of introducing an MDT for early rectal
cancer and found improvement in preoperative staging, a
reduction in margin positivity, and an increase in the use of
local excision.39 However, the statistical significance in that
study is questionable because the number of patients was
excessively low.
4.4. Quality of pathology reports
MDTs significantly affected the quality of pathology reports
(relative risk Z 4.85, 95% CI Z 1.34e17.46, p Z 0.01) in
one study,33 where good quality required measuring the
circumferential resection margin in millimeters. In addi-
tion, the number of lymph nodes examined in an MDT group
was significantly higher than that in a pre-MDT group (8.5
vs. 13.7, p < 0.001).35 Microsatellite instability analysis was
more likely to be performed if patients were under the care
of an MDT (29.6% vs. 10.6%, p < 0.001).34 These results
suggest that MDT meetings and discussions encourage pa-
thologists to improve their reports to fulfill guidelines and
provide more information for diagnosis and decision-making
regarding treatment planning.
4.5. Adjuvant chemotherapy
MDTs can provide suitable recommendations for adjuvant
chemotherapy for patients with colorectal cancer. Mac-
Dermid et al40 demonstrated that significantly more pa-
tients were prescribed adjuvant chemotherapy after theimplementation of an MDT approach, even after substaging
analysis (31.3% vs. 13.0%, p < 0.001; Dukes’ B, p Z 0.002;
Dukes’ C, p Z 0.004). A survey conducted in The
Netherlands showed a similar result. Patients with Stage III
colon cancer, who were diagnosed in hospitals with MDT
meetings and discussions, received adjuvant chemotherapy
more frequently than control group patients did
(OR Z 1.33, 95% CI Z 1.15e1.55, p < 0.05).23 Ye et al35
revealed that significantly fewer patients with Stages I
and IIA disease were prescribed adjuvant chemotherapy
after the implementation of an MDT approach (64% vs. 0%,
p < 0.001; 82% vs. 12%, p < 0.001). No significant differ-
ences were observed in the prescription of adjuvant
chemotherapy to patients with Stages IIB and III colon
cancer between pre-MDT and MDT groups (Stage IIB:
pZ 0.183; Stage IIIA: pZ 0.577; Stage IIIB: pZ 0.728; and
Stage IIIC: p Z 0.616).35
4.6. Chemotherapy for metastatic disease
For patients with metastatic disease, MDTs significantly
influenced the use of new chemotherapy regimens if liver
metastases were present (relative risk Z 6.41,
CIZ 1.34e30.64, pZ 0.02).33 However, no difference was
observed in the number of patients who were prescribed
palliative chemotherapy before and after the imple-
mentation of an MDT approach (p Z 0.750 and p Z 0.431,
respectively).35,40
4.7. Patient survival
Most studies have confirmed a positive effect of MDTs on
patient survival. However, because these studies on MDTs
were observational or retrospective, the effects of multiple
concurrent changes in cancer treatment and care should
always be considered when the study results are inter-
preted, particularly regarding the influence of MDTs on
patient outcome.
A population-based retrospective survey by Morris et al4
showed that a 25% increase in the MDT score was associated
with a 3% reduction in the risk of death for all patients with
colorectal cancer [hazard ratio (HR) Z 0.97, 95%
CIZ 0.94e0.99, pZ 0.01]. This reduction was significant in
patients with colon cancer (HR Z 0.96, 95%
CI Z 0.93e0.99, p < 0.01), but not in patients with rectal
cancer (HR Z 0.99, 95% CI Z 0.95e1.04, p Z 0.81).4 A
survey conducted in The Netherlands showed that mortality
in patients with colon cancer was slightly lower in an MDT
group than in a control group (HR Z 0.97, 95%
CI Z 0.94e0.99, p < 0.05), but not in patients with rectal
cancer (HR Z 0.96, 95% CI Z 0.92e1.01).23
MacDermid et al40 evaluated the effect of MDTs on the
survival of patients with colorectal cancer at a single
institution and demonstrated that MDT status was an in-
dependent predictor of survival (HR Z 0.73, 95%
CI Z 0.54e0.98, p Z 0.044). In a subgroup analysis, a
significantly improved 3-year survival rate was demon-
strated for Dukes’ C patients after MDT establishment (58%
vs. 66%, p Z 0.023), but not for Dukes’ B patients (76% vs.
70%, p Z 0.486). The median survival did not differ in pa-
tients with metastatic disease who underwent surgery
Colorectal cancer treatment 149before or after the implementation of an MDT approach (8
months vs. 11.9 months, p Z 0.234).40 Through a multi-
variate analysis, Ye et al35 revealed that management after
the commencement of an MDT approach was a major factor
that independently influenced overall survival (p < 0.001).
Lordan et al41 conducted a prospective survey on the
survival of patients with colorectal cancer who were rec-
ommended to undergo hepatic resection with or without an
MDT. Patients who were referred by the MDT for hepatic
resection had a 3-year overall survival rate of 67.5% and a 3-
year disease-free survival rate of 31.0%. Patients referred
directly without the MDT had a 3-year survival rate of 54.1%
and a 3-year disease-free survival rate of 37.6%. The dif-
ference in overall survival was significant (p < 0.001),
although the difference in disease-free survival was not
(p Z 0.205).41 In a survey in Germany, the median overall
survival time of patients with metastatic disease who were
treated with a multimodal strategy under MDT care was
significantly longer than that of patients who were treated
only with palliative chemotherapy (49 months vs. 22
months, p < 0.001).42 In addition, the difference in median
progression-free survival was considerably significant (18
months vs. 6 months, p < 0.001).42
5. Conclusion
Establishing MDTs for colorectal cancer care can lead to
more complete preoperative evaluation and higher rates of
access to multimodal therapies. Moreover, MDTs can
improve the quality of pathology reports, provide suitable
recommendations for adjuvant chemotherapy, and increase
overall survival in patients with colorectal cancer. To
enhance the quality of cancer care, government-affiliated
hospitals should encourage establishing MDTs.
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